logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 20 of 21 Items
Showing 1 - 20 of 21 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Commentary

Debate-Pro: manufacturers should assess the long-term stability of their antivenoms

Potet J
2024-08-21 • Emergency Medicine Journal: EMJ
2024-08-21 • Emergency Medicine Journal: EMJ
Journal Article
|
Commentary

Availability, accessibility and use of antivenom for snakebite envenomation in Africa with proposed strategies to overcome the limitations

Dalhat MM, Potet J, Mohammed A, Chotun N, Tesfahunei HA,  et al.
2023-02-26 • Toxicon: X
2023-02-26 • Toxicon: X
Africa remains one of the regions with the highest incident and burden of snakebite. The goal of the World Health Organization to halve the global burden of snakebite by 2030 can only be...
Journal Article
|
Commentary

Snakebite envenoming at MSF: A decade of clinical challenges and antivenom access issues

Potet J, Singh SN, Ritmeijer KKD, Sisay K, Alcoba G,  et al.
2022-12-21 • Toxicon: X
2022-12-21 • Toxicon: X
The medical humanitarian organization Médecins Sans Frontières (MSF) provides medical care in more than 70 countries and admits more than 7000 cases of snakebite in its facilities each y...
Journal Article
|
Commentary

Understanding and tackling snakebite envenoming with transdisciplinary research

Gutiérrez JM, Borri J, Giles-Vernick T, Duda R, Habib AG,  et al.
2022-11-17 • PLOS Neglected Tropical Diseases
2022-11-17 • PLOS Neglected Tropical Diseases
Journal Article
|
Commentary

Snakebites and COVID-19: two crises, one research and development opportunity

Martins D, Ribeiro I, Potet J
2021-10-25 • BMJ Global Health
2021-10-25 • BMJ Global Health
SUMMARY POINTS

• Despite inherent differences, Snakebite Envenoming and COVID-19 have much in common in terms of research and development (R&D) challenges and opportunities.
Journal Article
|
Research

Effect of artesunate-amodiaquine on mortality related to Ebola virus disease

Gignoux EM, Azman AS, de Smet M, Azuma P, Massaquoi M,  et al.
2016-01-07 • New England Journal of Medicine
2016-01-07 • New England Journal of Medicine
BACKGROUND
Malaria treatment is recommended for patients with suspected Ebola virus disease (EVD) in West Africa, whether systematically or based on confirmed malaria diagnosis. At t...
Journal Article
|
Letter

Legislation governing the US incentive scheme for neglected diseases needs to be amended, urges MSF

Reid J, Potet J, Athersuch K, Grovestock M, Sanjuan J
2014-09-30 • British Medical Journal (BMJ)
2014-09-30 • British Medical Journal (BMJ)
Journal Article
|
Commentary

Human african trypanosomiasis in the democratic republic of the congo: a looming emergency?

Hasker E, Lutumba P, Chappuis F, Kande V, Potet J,  et al.
2012-12-13 • PLOS Neglected Tropical Diseases
2012-12-13 • PLOS Neglected Tropical Diseases
Journal Article
|
Commentary

Antivenoms for Snakebite Envenoming: What Is in the Research Pipeline?

Alirol E, Lechevalier P, Zamatto F, Chappuis F, Alcoba G,  et al.
2015-09-10 • PLOS Neglected Tropical Diseases
2015-09-10 • PLOS Neglected Tropical Diseases
Journal Article
|
Research

Knowledge, attitude and practices of snakebite management amongest health workers in Cameroon: Need for continuous training and capacity building

Taieb F, Dub T, Madec Y, Tondeur L, Chippaux JP,  et al.
2018-10-25 • PLOS Neglected Tropical Diseases
2018-10-25 • PLOS Neglected Tropical Diseases
Snakebite has only recently been recognized as a neglected tropical disease by the WHO. Knowledge regarding snakebites and its care is poor both at the population level, and at the healt...
Journal Article
|
Review

Uncharted territory of the epidemiological burden of cutaneous leishmaniasis in sub-Saharan Africa-A systematic review

Sunyoto T, Verdonck K, el Safi S, Potet J, Picado A,  et al.
2018-10-25 • PLOS Neglected Tropical Diseases
2018-10-25 • PLOS Neglected Tropical Diseases
Cutaneous leishmaniasis (CL) is the most frequent form of leishmaniasis, with 0.7 to 1.2 million cases per year globally. However, the burden of CL is poorly documented in some regions. ...
Journal Article
|
Review

Liposomal amphotericin B as a treatment for human leishmaniasis

Balasegaram M, Ritmeijer KKD, Lima MA, Burza S, Ortiz Genovese G,  et al.
2012-11-20 • Expert Opinion on Emerging Drugs
2012-11-20 • Expert Opinion on Emerging Drugs
Journal Article
|
Review

Access to antivenoms in the developing world: a multidisciplinary analysis

Potet J, Beran D, Ray N, Alcoba G, Habib AG,  et al.
2021-10-26 • Toxicon: X
2021-10-26 • Toxicon: X
Access to safe, effective, quality-assured antivenom products that are tailored to endemic venomous snake species is a crucial component of recent coordinated efforts to reduce the globa...
Journal Article
|
Review

Visceral leishmaniasis in Somalia: a review of epidemiology and access to care

Sunyoto T, Potet J, Boelaert M
2017-03-09 • PLOS Neglected Tropical Diseases
2017-03-09 • PLOS Neglected Tropical Diseases
Somalia, ravaged by conflict since 1991, has areas endemic for visceral leishmaniasis (VL), a deadly parasitic disease affecting the rural poor, internally displaced, and pastoralists. V...
Journal Article
|
Research

Exploring global and country-level barriers to an effective supply of leishmaniasis medicines and diagnostics in eastern Africa: a qualitative study

Sunyoto T, Potet J, den Boer ML, Ritmeijer KKD, Postigo JAR,  et al.
2019-05-01 • BMJ Open
2019-05-01 • BMJ Open
OBJECTIVES:
To understand stakeholders' perceptions of the access barriers to quality-assured diagnostics and medicines for leishmaniasis in the high-burden region of eastern Africa...
Journal Article
|
Research

Economic impact of thermostable vaccines

Lee BY, Wedlock PT, Haidari LA, Elder K, Potet J,  et al.
2017-04-25 • Vaccine
2017-04-25 • Vaccine
BACKGROUND
While our previous work has shown that replacing existing vaccines with thermostable vaccines can relieve bottlenecks in vaccine supply chains and thus increase vaccine av...
Journal Blog
|
Perspective

Poised to strike: global plan to tackle snakebite demands urgent action

Bradley J, Potet J
2018-06-15
2018-06-15
Journal Article
|
Review

Snakebite envenoming in humanitarian crises and migration: A scoping review and the Médecins Sans Frontières experience

Alcoba G, Potet J, Vatrinet R, Singh SN, Nanclares C,  et al.
2022-03-01 • Toxicon: X
2022-03-01 • Toxicon: X
Snakebite envenoming is a public health concern in many countries affected by humanitarian crises. Its magnitude was recognized internationally but associations between snakebite peaks a...
Journal Article
|
Commentary

Control of visceral leishmaniasis in East Africa: fragile progress, new threats

Dahl EH, Hamdan M, Mabrouk L, Matendechero S, Mengistie TB,  et al.
2021-08-13 • BMJ Global Health
2021-08-13 • BMJ Global Health
SUMMARY BOX

• Significant progress has been made in reducing the global burden of visceral leishmaniasis, but new threats are on the horizon.
• Funding for elimination of ...
Journal Article
|
Commentary

Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most

Sunyoto T, Potet J, Boelaert M
2018-05-03 • BMJ Global Health
2018-05-03 • BMJ Global Health
Miltefosine, the only oral drug approved for the treatment of leishmaniasis-a parasitic disease transmitted by sandflies-is considered as a success story of research and development (R&D...